BMC oral health · 2025
Edaravone attenuates doxorubicin-induced oral mucosal injury via modulation of oxidative stress, inflammatory signaling, and the SIRT1/TLR4/NF-kB/ACE2 axis in rats.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zeytinoglu Mert, Erdil Aras, Çolak Sefa, Demirsoy Mustafa Sami, Akin Ali Tuğrul, Değer Necla, Karabulut Derya, Gül Serdar Savaş, Aygun Hatice, Erbaş Oytun
Аннотация
BACKGROUND: Oral mucositis (OM) is a common complication of chemotherapy, particularly with anthracyclines like doxorubicin (DOX), which induce oxidative stress and inflammation. This study investigated the protective effects of edaravone (EDO), a free radical scavenger, against DOX-induced oral mucosal injury.
METHODS: Twenty-eight male Wistar rats were randomly divided into four groups (n = 7): Control, DOX (18 mg/kg, i.p., days 19-21), and two EDO + DOX groups (1 or 30 mg/kg EDO daily for 21 days). On day 22, tongue tissues and plasma were analyzed for oxidative stress markers (MDA, GSH, SOD, TAS, TOS) and cytokines (TNF-α, IL-6, IL-1β, IL-10). NF-κB, SIRT1, and TLR4 expression were assessed via immunohistochemistry and ELISA, while ACE2 expression was evaluated by immunohistochemistry.
RESULTS: DOX significantly upregulated ACE2 (p < 0.001), TLR4 (p < 0.001), NF-κB (p < 0.001), and proinflammatory cytokines in plasma and tongue tissue (TNF-α, IL-6, IL-1β; all p < 0.01), while reducing IL-10 (p < 0.001), GSH (p = 0.002), SOD (p = 0.001), and SIRT1 (p < 0.001). EDA treatment reduced ACE2 and TLR4 expression, with 30 mg/kg normalizing ACE2 (p = 0.978 vs. control). EDO restored antioxidant markers and significantly lowered MDA, TOS, cytokines, and NF-κB (all p < 0.05). Histological injury and inflammation scores also improved significantly (p < 0.001).
CONCLUSION: Edaravone effectively attenuates DOX-induced mucosal injury by modulating oxidative stress, inflammatory signaling, and TLR4/ACE2 pathways, suggesting therapeutic potential in mucosal protection.
METHODS: Twenty-eight male Wistar rats were randomly divided into four groups (n = 7): Control, DOX (18 mg/kg, i.p., days 19-21), and two EDO + DOX groups (1 or 30 mg/kg EDO daily for 21 days). On day 22, tongue tissues and plasma were analyzed for oxidative stress markers (MDA, GSH, SOD, TAS, TOS) and cytokines (TNF-α, IL-6, IL-1β, IL-10). NF-κB, SIRT1, and TLR4 expression were assessed via immunohistochemistry and ELISA, while ACE2 expression was evaluated by immunohistochemistry.
RESULTS: DOX significantly upregulated ACE2 (p < 0.001), TLR4 (p < 0.001), NF-κB (p < 0.001), and proinflammatory cytokines in plasma and tongue tissue (TNF-α, IL-6, IL-1β; all p < 0.01), while reducing IL-10 (p < 0.001), GSH (p = 0.002), SOD (p = 0.001), and SIRT1 (p < 0.001). EDA treatment reduced ACE2 and TLR4 expression, with 30 mg/kg normalizing ACE2 (p = 0.978 vs. control). EDO restored antioxidant markers and significantly lowered MDA, TOS, cytokines, and NF-κB (all p < 0.05). Histological injury and inflammation scores also improved significantly (p < 0.001).
CONCLUSION: Edaravone effectively attenuates DOX-induced mucosal injury by modulating oxidative stress, inflammatory signaling, and TLR4/ACE2 pathways, suggesting therapeutic potential in mucosal protection.